| Lineage |
Neuron > Dysregulated |
| Markers |
p-CREB, p-ERK, p-mTOR, p-STAT3, NF-κB |
| Brain Regions |
Cerebral Cortex, Hippocampus, Basal Ganglia, Limbic System |
| Disease Relevance |
Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Autism, Schizophrenia |
Dysregulated Neurons plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Dysregulated neurons represent a pathological state characterized by abnormal control of intracellular signaling pathways, disrupted homeostasis, and impaired adaptive responses to environmental challenges. Unlike neurons that are simply hyperactive or hypoactive, dysregulated neurons exhibit fundamental errors in their ability to sense, interpret, and respond to cellular signals [1]. This loss of regulatory control manifests at multiple levels: molecular signaling cascades, gene expression programs, metabolic pathways, and network-level computations [2].
The concept of neuronal dysregulation extends beyond simple activity changes. It encompasses the breakdown of intricate feedback mechanisms that normally maintain cellular equilibrium. These mechanisms include homeostatic plasticity, stress response pathways, trophic factor signaling, and circadian regulation [3].
- cAMP/PKA pathway: Abnormal cAMP dynamics disrupt downstream phosphorylation cascades [4]
- MAPK/ERK pathway: Constitutive or impaired ERK activation alters neuronal plasticity [5]
- PI3K/Akt/mTOR pathway: Dysregulated mTOR signaling affects protein synthesis and autophagy [6]
- Calcium signaling: Impaired calcium homeostasis disrupts numerous downstream processes [7]
- CREB dysfunction: Altered CREB-mediated transcription affects survival and plasticity genes [8]
- NF-κB activation: Chronic inflammation drives inappropriate gene expression [9]
- FOXO mislocalization: Impaired stress response gene regulation [10]
- Epigenetic alterations: Histone modifications and DNA methylation changes [11]
- Glucose metabolism: Altered glycolysis and oxidative phosphorylation [12]
- Lipid metabolism: Disrupted membrane composition and lipid signaling [13]
- Amino acid metabolism: Impaired neurotransmitter synthesis [14]
- Energy homeostasis: ATP/AMP ratio disruptions affect all cellular processes [15]
- Abnormal spine morphology: Irregular spine shapes indicate synaptic instability [16]
- Impaired vesicle cycling: Altered release probability and replenishment [17]
- Receptor trafficking errors: Mislocalized ionotropic and metabotropic receptors [18]
- Synaptic protein aggregates: Misfolded proteins at presynaptic terminals [19]
- Microtubule instability: Tau pathology disrupts axonal transport [20]
- Actin dynamics alterations: Impaired spine plasticity and motility [21]
- Intermediate filament disorders: Neurofilament abnormalities affect axonal integrity [22]
- Axonal transport deficits: Kinesin/dynein dysfunction [23]
- Mitochondrial fragmentation: Impaired fusion/fission balance [24]
- ER stress: Unfolded protein response activation [25]
- Lysosomal impairment: Autophagy-lysosome pathway deficits [26]
- Golgi apparatus fragmentation: Disrupted protein processing [27]
- APP processing dysregulation: Abnormal amyloid precursor protein cleavage [28]
- Aβ oligomer toxicity: Synaptic dysregulation through multiple mechanisms [29]
- BACE1 hyperactivity: Enhanced amyloidogenic processing [30]
- Hyperphosphorylation: Dissociation of tau from microtubules [31]
- Oligomer formation: Toxic tau species spread between neurons [32]
- Axonal transport disruption: Tau-mediated transport deficits [33]
- NMDA receptor overactivation: Excitotoxic calcium influx [34]
- ER calcium depletion: Store-operated calcium entry abnormalities [35]
- Mitochondrial calcium overload: Permeability transition pore opening [36]
- Oligomer formation: Toxic alpha-synuclein species [37]
- Lewy body formation: Intraneuronal inclusions disrupt function [38]
- Synaptic vesicle binding: Impairs neurotransmitter release [39]
- Tyrosine hydroxylase dysfunction: Impaired dopamine synthesis [40]
- Vesicular monoamine transporter: Altered dopamine packaging [41]
- Dopamine receptor signaling: Downstream pathway dysregulation [42]
- Complex I deficiency: Reduced ATP production [43]
- ROS overproduction: Oxidative stress accumulation [44]
- Mitophagy impairment: Accumulation of dysfunctional mitochondria [45]
- Neurexin/neuroligin dysfunction: Impaired synapse formation [46]
- SHANK protein deficits: Postsynaptic density abnormalities [47]
- mTOR hyperactivation: Enhanced protein synthesis [48]
- Excitation-inhibition imbalance: Altered E/I ratio [49]
- Cortical connectivity changes: Modified network properties [50]
- Sensory processing abnormalities: Enhanced sensory responses [51]
- D1 hypofunction: Prefrontal cortex working memory deficits [52]
- D2 hyperfunction: Striatal signaling abnormalities [53]
- Presynaptic dopamine dysfunction: Altered synthesis and release [54]
- NMDA receptor hypofunction: Synaptic plasticity deficits [55]
- AMPA receptor trafficking: Altered receptor composition [56]
- Metabotropic glutamate signaling: Group I mGluR dysfunction [57]
- Phosphodiesterase inhibitors: Enhance cAMP signaling [58]
- MAPK pathway modulators: Normalize ERK activity [59]
- mTOR inhibitors: Reduce hyperactivation in autism [60]
- Ketogenic diet: Alternative energy metabolism [61]
- Pyruvate supplementation: Enhanced metabolic support [62]
- Antioxidants: Reduce oxidative stress [63]
- Viral vector delivery: Target specific dysregulated pathways [64]
- CRISPR-based approaches: Correct genetic causes [65]
- RNA therapeutics: Modulate expression of dysregulated genes [66]
- Patient-derived iPSCs: Model disease-specific dysregulation [67]
- Primary neuron cultures: Manipulate signaling pathways [68]
- Organoid systems: Complex network dysregulation [69]
- Transgenic models: Disease-causing mutations [70]
- Knockout models: Specific pathway disruption [71]
- [Optogenetic manipulation: Precise temporal control of signaling [72]
Dysregulated Neurons plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Dysregulated Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Zhang, Y. et al. (2007). Neuronal signaling pathways. Cell
- Greengard, P. (2001). The neurobiology of slow synaptic transmission. Science
- Turrigiano, G.G. (2000). Homeostatic plasticity in neuronal networks. Trends in Neurosciences
- Sanes, J.R. & Lichtman, J.W. (1999). Development of the vertebrate neuromuscular junction. Annual Review of Neuroscience
- Thomas, G.M. & Huganir, R.L. (2004). MAPK cascade signalling and synaptic plasticity. Nature Reviews Neuroscience
- Swiech, L. et al. (2011). TOR signaling in neurons. Developmental Biology
- Berridge, M.J. (1998). Neuronal calcium signaling. Neuron
- Lonze, B.E. & Ginty, D.D. (2002). Function and regulation of CREB. Neuron
- Mattson, M.P. & Camandola, S. (2001). NF-kappaB in neuronal plasticity and neurodegenerative disorders. Journal of Clinical Investigation
- Burgering, B.M. & Kops, G.J. (2002). Cell cycle and death control by Forkheads. Trends in Biochemical Sciences
- Grayson, D.R. et al. (2005). Epigenetic regulation in neurodevelopment and disease. Brain Research Reviews
- Vander Heiden, M.G. et al. (2009). Understanding the Warburg effect. Science
- Pichler, G. et al. (2017). Neural lipid metabolism. Annals of Neurology
- Shulman, R.G. & Rothman, D.L. (2001). Brain energy metabolism. Annual Review of Physiology
- Nicholls, D.G. (2005). Mitochondrial calcium function and dysfunction. Annual Review of Physiology
- Yuste, R. & Bonhoeffer, T. (2001). Morphological changes in dendritic spines. Annual Review of Neuroscience
- Sudhof, T.C. (2004). The synaptic vesicle cycle. Annual Review of Neuroscience
- Luscher, C. et al. (1999). Synaptic plasticity and dynamic modulation of the postsynaptic membrane. Nature Neuroscience
- Ross, C.A. & Poirier, M.A. (2004). Protein aggregation and neurodegenerative disease. Nature Medicine
- Mandelkow, E. & Mandelkow, E. (2002). Tau in physiology and pathology. Nature Reviews Neuroscience
- Calabrese, B. et al. (2006). Actin and the spine synapse. The Neuroscientist
- Nixon, R.A. & Lee, M.Y. (2000). Neurofilament pathology. Journal of Neuropathology & Experimental Neurology
- Goldstein, L.S. (2001). Molecular mechanisms of neurodegeneration. Nature Reviews Neuroscience
- Detmer, S.A. & Chan, D.C. (2007). Functions and dysfunctions of mitochondrial dynamics. Nature Reviews Neuroscience
- Kaufman, R.J. (1999). Stress signaling from the lumen of the ER. Genes & Development
- Nixon, R.A. (2007). Autophagy, amyloidogenesis and Alzheimer disease. Journal of Cell Science
- Gonatas, N.K. et al. (2006). Fragmentation of the Golgi apparatus. Brain Research Reviews
- Selkoe, D.J. (2001). Alzheimer's disease: genes, proteins, and therapy. Physiological Reviews
- Walsh, D.M. & Selkoe, D.J. (2007). A beta oligomers. Neuron
- Vassar, R. (2004). BACE1: the beta-secretase enzyme in Alzheimer's disease. Journal of Molecular Neuroscience
- Ballatore, C. et al. (2007). Tau-mediated neurodegeneration. Nature Reviews Neuroscience
- Lasagna-Reeves, C.A. et al. (2011). Tau oligomers. Journal of Alzheimer's Disease
- Mandelkow, E. et al. (2003). Tau pathology and axonal transport. Traffic
- Hynd, M.R. et al. (2004). Glutamate-mediated excitotoxicity in Alzheimer's disease. Neurochemistry International
- Berridge, M.J. (2010). Calcium signalling and Alzheimer's disease. Neurochemical Research
- Mattson, M.P. (2007). Calcium and neurodegeneration. Aging Cell
- Spillantini, M.G. & Goedert, M. (2013). The alpha-synucleinopathies. Handbook of Clinical Neurology
- Wakabayashi, K. et al. (1997). Lewy bodies in the cerebral cortex. Acta Neuropathologica
- Burre, J. et al. (2010). Alpha-synuclein promotes SNARE-complex assembly. Journal of Neuroscience
- Kumer, S.C. & Vrana, K.E. (1996). Intricate regulation of tyrosine hydroxylase. Journal of Neurochemistry
- Eiden, L.E. et al. (2004). The vesicular monoamine transporter. Journal of Molecular Neuroscience
- Missale, C. et al. (1998). Dopamine receptors. Physiological Reviews
- Schapira, A.H. (2008). Mitochondrial dysfunction in neurodegenerative Parkinson's disease. Science
- Lin, M.T. & Beal, M.F. (2006). Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature
- Youle, R.J. & Narendra, D.P. (2011). Mechanisms of mitophagy. Nature Reviews Molecular Cell Biology
- Craig, A.M. & Kang, Y. (2007). Neurexin-neuroligin synapses. Current Opinion in Neurobiology
- Sheng, M. & Kim, E. (2000). The postsynaptic density. Journal of Cell Science
- Sahin, M. & Sur, M. (2015). Genes, circuits, and therapies for autism. Nature
- Rubenstein, J.L. & Merzenich, M.M. (2003). Model of autism. Genes, Brain and Behavior
- Geschwind, D.H. & Levitt, P. (2007). Autism spectrum disorders. Current Opinion in Neurobiology
- Marco, E.J. et al. (2011). Sensory processing in autism. Pediatric Research
- Goldman-Rakic, P.S. (1999). The dopaminergic mind. Neuropsychopharmacology
- Kapur, S. & Seeman, P. (2002). Dopamine D2 receptor blockade. Molecular Psychiatry
- Abi-Dargham, A. (2004). Do we still believe in the dopamine hypothesis? International Journal of Neuropsychopharmacology
- Coyle, J.T. & Tsai, G. (2004). NMDA receptor function in schizophrenia. American Journal of Psychiatry
- Malenka, R.C. & Bear, M.F. (2004). LTP and LTD. Neuron
- Conn, P.J. et al. (2009). Metabotropic glutamate receptors. Nature Reviews Drug Discovery
- Menniti, F.S. et al. (2010). PDE inhibitors for CNS diseases. Nature Reviews Drug Discovery
- Roskoski, R. (2012). ERK1/2 MAP kinases. Pharmacology Research
- Sabbagh, J.J. et al. (2013). Targeting mTOR for autism spectrum disorders. Nature Reviews Drug Discovery
- Paoli, A. et al. (2013). Beyond weight loss. Nutrition Research Reviews
- Zilberter, Y. & Zilberter, T. (2017). Pyruvate in brain metabolism. Journal of Neurochemistry
- Sayre, L.M. et al. (2008). Oxidative stress in neurodegeneration. Free Radical Biology and Medicine
- Fink, M.A. et al. (2000). Gene therapy for neurological disorders. Nature Reviews Drug Discovery
- Hsu, P.D. et al. (2013). Development and applications of CRISPR-Cas9. Nature Methods
- Kumar, L.D. & Karthik, R. (2016). RNA therapeutics. Advances in Experimental Medicine and Biology
- Kondo, T. et al. (2013). iPSC models of Alzheimer's disease. Cell Stem Cell
- Banker, G. & Goslin, K. (1988). Developments in neuronal cell culture. Nature
- Lancaster, M.A. & Knoblich, J.A. (2014). Organogenesis in a dish. Science
- Jankord, R. & Herman, J.P. (2008). Limbic regulation of hypothalamic-pituitary-adrenocortical function. Stress
- Zhang, J. et al. (2010). Knockout mouse models. Neurochemical Research
- Zhang, F. et al. (2010). Optogenetics in neural systems. Neuron